8 completed. 8 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 4 | Completed 4 |
Follow Dermatofibrosarcoma: new trials by email Literature Review of Dermatofibrosarcoma trials Research Report on Dermatofibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas DCC-3014, Avelumab - Sarcoma, Advanced Sarcoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 32 | 2020-01-22 | 2025-08-28 |
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Completed | BioAtla, Inc. | 245 | 2018-02-15 | 2025-09-23 |
| Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 16 | 2017-03-10 | 2023-08-16 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors nab-paclitaxel - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Celgene | 107 | 2013-12-04 | 2019-12-27 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate Imatinib mesylate, Cyclophosphamide (Dosing level 1 ), Imatinib mesylate, Cyclophosphamide (Dosing level 2), Imatinib mesylate, Cyclophosphamide (Dosing level 3) - Cancer | Phase 1 | Completed | Centre Oscar Lambret | 26 | 2009-02-09 | 2026-09-17 |
| Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2008-06-01 | 2016-05-17 |
| Imatinib in Dermatofibrosarcoma Protuberans (DFSP) Imatinib (Glivec) - Dermatofibrosarcoma | Phase 1 / Phase 2 | Completed | Dermatologic Cooperative Oncology Group | 30 | 2004-01-01 | 2011-07-29 |
Histiocytoma, Malignant Fibrous (5) · Sarcoma (5) · Fibrosarcoma (4) · Liposarcoma (4) · Hemangiosarcoma (3) · Leiomyosarcoma (3) · Neoplasms (3) · Neurofibrosarcoma (3) · Rhabdomyosarcoma (3) · Sarcoma, Synovial (3) · Chondrosarcoma, Extraskeletal Myxoid (2) · Desmoplastic Small Round Cell Tumor (2) · Gastrointestinal Stromal Tumors (2) · Malignant mesenchymal tumor (2)
Neoplasms by Histologic Type (8) · Neoplasms, Connective Tissue (8) · Neoplasms, Connective and Soft Tissue (8) · Neoplasms, Fibrous Tissue (8) · Histiocytoma (5) · Neoplasms (5) · Neoplasms, Nerve Tissue (5) · Fibrosarcoma (4) · Neoplasms, Adipose Tissue (4) · Neoplasms, Muscle Tissue (4) · Myosarcoma (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Vascular Tissue (3) · Nerve Sheath Neoplasms (3)
Doxorubicin (2) · Imatinib Mesylate (2) · 130-nm albumin-bound paclitaxel (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Albumin-Bound Paclitaxel (1) · Blood Specimen Collection (1) · Cyclophosphamide (1) · HhAntag691 (1) · Immune Checkpoint Inhibitors (1) · avelumab (1) · cixutumumab (1) · ribociclib (1)
National Cancer Institute (NCI) (2) · BioAtla, Inc. (1) · Celgene (1) · Centre Oscar Lambret (1) · Dermatologic Cooperative Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · OHSU Knight Cancer Institute (1)
United States (6) · France (2) · Canada (1) · Germany (1) · Hong Kong (1) · Italy (1) · Spain (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Dirk Schadendorf, MD (1) · Ileana Elias, M.D. (1) · Lara E Davis (1) · Mrinal Gounder (1) · Rashmi Chugh (1) · Sandra D'Angelo, MD (1) · Selma Ugurel, MD (1)
PMID 25858498, PMID 31401903, PMID 32554315, PMID 38579194
2008 (1), N01CM00071 (1), N01CM62206 (1), P30CA008748 (1), P30CA014599 (1), U01CA069856 (1)